What is the proper protocol for initiating and managing a heparin drip?

Heparin Drip Administration Protocol

For therapeutic anticoagulation in adults, initiate heparin with an 80 U/kg IV bolus followed by a continuous infusion of 18 U/kg/hour, checking aPTT at 6 hours and adjusting per weight-based nomogram to maintain aPTT 1.5-2 times control (approximately 60-85 seconds). 1

Initial Dosing

Weight-based dosing is superior to fixed dosing and should be used for all patients requiring therapeutic anticoagulation 1:

• Bolus dose: 80 U/kg IV push 1
• Initial infusion rate: 18 U/kg/hour as continuous IV infusion 1
• Alternative FDA-approved regimen: 5,000 units IV bolus followed by 20,000-40,000 units/24 hours (approximately 1,000-1,667 units/hour) 2

The weight-based approach (80 U/kg bolus + 18 U/kg/hour) achieves therapeutic anticoagulation more rapidly and reduces recurrent thromboembolism risk from 25% to 2% when therapeutic aPTT is achieved early 1.

Monitoring Protocol

Timing of Laboratory Tests

• First aPTT: Draw 6 hours after initiating the bolus dose 1, 2
• Subsequent aPTTs: Every 6 hours after each dose adjustment until therapeutic 1
• Once stable: Check aPTT every 24 hours or per institutional protocol 2
• Baseline labs: Obtain aPTT, INR, platelet count, hematocrit before starting therapy 2

Ongoing Monitoring

• Platelet counts: Monitor periodically throughout therapy to detect heparin-induced thrombocytopenia (HIT) 1, 2
• Hematocrit and occult blood: Check periodically regardless of administration route 2

Dose Adjustment Nomogram

Use the following weight-based adjustments based on aPTT results 1:

aPTT Result	Bolus	Rate Change	Repeat aPTT
<35 seconds (<1.2× control)	80 U/kg	Increase by 4 U/kg/hour	6 hours
35-45 seconds (1.2-1.5× control)	40 U/kg	Increase by 2 U/kg/hour	6 hours
46-70 seconds (1.5-2.3× control)	None	No change	Next morning or per protocol
71-90 seconds (2.3-3× control)	None	Decrease by 2 U/kg/hour	6 hours
>90 seconds (>3× control)	None	Hold infusion 1 hour, then decrease by 3 U/kg/hour	6 hours

Therapeutic Target

The therapeutic aPTT range is 1.5-2 times the control value (typically 60-85 seconds), which correlates with anti-Factor Xa levels of 0.3-0.7 units/mL 1, 2. Failure to achieve this range within the first 24 hours increases recurrent thromboembolism risk 10-22 fold 1.

Preparation and Administration

Mixing the Infusion

• Standard concentration: Mix heparin in 0.9% sodium chloride or compatible solution 2
• Critical mixing step: Invert the IV bag at least 6 times to ensure adequate mixing and prevent pooling of heparin 2
• Verify correct vial: Confirm you have the correct concentration to avoid fatal dosing errors 2

Route of Administration

• Preferred route: Continuous IV infusion via dedicated line 2
• Avoid: Intramuscular injection due to high risk of hematoma 2

Special Populations

Pediatric Dosing

• Initial bolus: 75-100 U/kg IV over 10 minutes 2
• Infants <2 months: 25-30 U/kg/hour (highest requirements) 2
• Children >1 year: 18-20 U/kg/hour 2
• Target aPTT: 60-85 seconds (anti-Xa 0.35-0.70 units/mL) 2
• Use preservative-free formulations in neonates and infants 2

Obese Patients

Recent evidence suggests lower weight-adjusted doses may be needed in obese patients to achieve target anticoagulation 3. Consider using actual body weight but monitor closely, as body mass index inversely correlates with heparin dose requirements 3.

Transitioning to Oral Anticoagulation

Converting to Warfarin

• Overlap period: Continue full-dose heparin for several days until INR reaches stable therapeutic range (typically INR 2-3) 2, 4
• Early initiation: Start warfarin on day 1 or 2 of heparin therapy to reduce hospital length of stay by approximately 4 days 1
• Discontinuation: Stop heparin without tapering once INR is therapeutic for 24 hours 2

Converting to Direct Oral Anticoagulants

• For continuous infusion: Stop heparin immediately after administering first dose of oral anticoagulant 2
• For intermittent dosing: Start oral anticoagulant 0-2 hours before next scheduled heparin dose 2

Critical Pitfalls to Avoid

Subtherapeutic Anticoagulation

The most dangerous error is failing to achieve therapeutic aPTT within 24 hours, which increases recurrent VTE risk dramatically 1. This occurs in approximately 50% of patients when using lower initial doses 1.

Monitoring Errors

• Do not wait until "next morning" for first aPTT—check at 6 hours 1
• Do not use aPTT alone in critically ill patients; consider anti-Xa monitoring if available 5
• Do not forget platelet monitoring to detect HIT early 1, 2

Dosing Errors

• Verify vial concentration before drawing up dose to prevent 10-fold errors 2
• Mix IV bags thoroughly by inverting 6 times to prevent bolus effect from pooled heparin 2
• Adjust for renal function: Heparin clearance involves both saturable and renal mechanisms 1

Alternative Monitoring: Anti-Xa Assay

While aPTT remains standard, anti-Xa monitoring may be superior in critically ill patients and those with aPTT confounders 5. Target anti-Xa range is 0.3-0.7 units/mL 2, 5. Weight-based protocols using anti-Xa achieve therapeutic levels in 52% of patients at 6 hours and 92% within 24 hours 6.